Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus , Lentivirus, Plasmids, Others), By Workflow By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

Viral Vectors and Plasmid DNA Manufacturing Market

The viral vectors and plasmid DNA manufacturing market was valued at $5.3 billion in 2023 and is projected to reach $34.0 billion by 2033, growing at a CAGR of 20.4% from 2024 to 2033.

Viral vector and plasmid DNA are the crucial components of genetic engineering, utilized for diverse purposes such as gene therapy and vaccine production. A viral vector is a form of molecular vehicle used to transfer genetic information to the cells either through gene expression or integration of genetic material into the cell's DNA. Plasmid DNA is an extrachromosomal circular piece of DNA present in bacteria. It serves as a vector for gene cloning, and gene therapy. The manufacturing of viral vectors and plasmid DNA is accomplished through various methods such as cell culture systems, purification processes, or bacterial fermentation.

Increase in the prevalence of genetic disorders and advancements in technology have facilitated the execution of gene therapies, thereby driving the growth of the viral vectors and plasmid DNA manufacturing market. In addition, rise in R&D activities due to surge in investments & support from government and regulatory agencies such as the Food and Drug administration is boosting the demand for the manufacturing for viral vectors and plasmid DNA. To enhance the scalability of production, the trend of using AI and ML algorithms is gaining prominence. The algorithm helps in identifying the precise requirements and ideal conditions to maximize the production of vectors and plasmid.

However, preventing contamination during manufacturing is challenging as a tiny foreign particle is capable of spoiling the entire production batch. This challenge significantly restrains the growth of the viral vectors and plasmid DNA manufacturing market. In addition, the procurement and maintenance of the equipment required for production is highly expensive, which limits several small-scale firms and laboratories from investing, hence hampering the market growth. Moreover, discrepancies in the regulatory process across the globe restrict the utility of the vectors and plasmid in certain regions. For instance, the European guidelines have mandated the compliance of products with the current good manufacturing practices standards at all stages of production. Contrarily, as per the U.S. Food and Drug Administration, it is acceptable that some materials and all relevant attributes or acceptance criteria remain unknown at stage 1 of product development.

Segment Review

The viral vectors and plasmid DNA manufacturing market is segmented into vector type, workflow, application, end user, and region. On the basis of vector type, the market is divided into adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Depending on workflow, it is bifurcated into upstream manufacturing and downstream manufacturing. As per application, it is classified into antisense & RNAi therapy, antisense & RNAi therapy, cell therapy, vaccinology, and research applications. According to end user, it is categorized into pharmaceutical & biopharmaceutical companies and research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of vector type, the adeno-associated virus (AAV) segment dominated the market in 2023.

Depending on workflow, the downstream manufacturing segment accounted for a high market share in 2023.

As per application, the vaccinology segment acquired a high stake in the market in 2023.

According to end user, the research institutes segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global viral vectors and plasmid DNA manufacturing market include Merck KGaA, Lonza Group AG, FUJIFILM Corporation, thermo fisher scientific, Cobra Biologics, Catalent Inc., WuXi Biologics., TakarBio Inc, Waisman Biomanufacturing, LLC, and Genezen laboratories. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Vector Type

Adenovirus
Retrovirus
Adeno-Associated Virus (AAV)
Lentivirus
Plasmids
Others

By Workflow

Upstream Manufacturing
Downstream Manufacturing

By Application

Antisense RNAi Therapy
Antisense RNAi Therapy
Cell Therapy
Vaccinology
Research Applications

By End User

Pharmaceutical Biopharmaceutical Companies
Research Institutes

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Merck KGaA
Lonza Group AG
FUJIFILM Corporation
Thermo Fisher Scientific Inc.
Cobra Biologics
Catalent Inc.
WuXi Biologics.
TakarBio Inc
Waisman Biomanufacturing, LLC
Genezen laboratories

Product Code: A324540

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Vector Type
4.2. Adenovirus
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Retrovirus
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Adeno-Associated Virus (AAV)
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
4.5. Lentivirus
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
4.6. Plasmids
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
4.7. Others
- 4.7.1. Key Market Trends, Growth Factors and Opportunities
- 4.7.2. Market Size and Forecast, By Region
- 4.7.3. Market Share Analysis, By Country

CHAPTER 5: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Workflow
5.2. Upstream Manufacturing
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Downstream Manufacturing
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country

CHAPTER 6: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Application
6.2. Antisense RNAi Therapy
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Antisense RNAi Therapy
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Cell Therapy
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
6.5. Vaccinology
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country
6.6. Research Applications
- 6.6.1. Key Market Trends, Growth Factors and Opportunities
- 6.6.2. Market Size and Forecast, By Region
- 6.6.3. Market Share Analysis, By Country

CHAPTER 7: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By End User
7.2. Pharmaceutical Biopharmaceutical Companies
- 7.2.1. Key Market Trends, Growth Factors and Opportunities
- 7.2.2. Market Size and Forecast, By Region
- 7.2.3. Market Share Analysis, By Country
7.3. Research Institutes
- 7.3.1. Key Market Trends, Growth Factors and Opportunities
- 7.3.2. Market Size and Forecast, By Region
- 7.3.3. Market Share Analysis, By Country

CHAPTER 8: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION

8.1. Market Overview
- 8.1.1 Market Size and Forecast, By Region
8.2. North America
- 8.2.1. Key Market Trends and Opportunities
- 8.2.2. Market Size and Forecast, By Vector Type
- 8.2.3. Market Size and Forecast, By Workflow
- 8.2.4. Market Size and Forecast, By Application
- 8.2.5. Market Size and Forecast, By End User
- 8.2.6. Market Size and Forecast, By Country
- 8.2.7. U.S. Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.2.7.1. Market Size and Forecast, By Vector Type
  - 8.2.7.2. Market Size and Forecast, By Workflow
  - 8.2.7.3. Market Size and Forecast, By Application
  - 8.2.7.4. Market Size and Forecast, By End User
- 8.2.8. Canada Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.2.8.1. Market Size and Forecast, By Vector Type
  - 8.2.8.2. Market Size and Forecast, By Workflow
  - 8.2.8.3. Market Size and Forecast, By Application
  - 8.2.8.4. Market Size and Forecast, By End User
- 8.2.9. Mexico Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.2.9.1. Market Size and Forecast, By Vector Type
  - 8.2.9.2. Market Size and Forecast, By Workflow
  - 8.2.9.3. Market Size and Forecast, By Application
  - 8.2.9.4. Market Size and Forecast, By End User
8.3. Europe
- 8.3.1. Key Market Trends and Opportunities
- 8.3.2. Market Size and Forecast, By Vector Type
- 8.3.3. Market Size and Forecast, By Workflow
- 8.3.4. Market Size and Forecast, By Application
- 8.3.5. Market Size and Forecast, By End User
- 8.3.6. Market Size and Forecast, By Country
- 8.3.7. Germany Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.3.7.1. Market Size and Forecast, By Vector Type
  - 8.3.7.2. Market Size and Forecast, By Workflow
  - 8.3.7.3. Market Size and Forecast, By Application
  - 8.3.7.4. Market Size and Forecast, By End User
- 8.3.8. France Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.3.8.1. Market Size and Forecast, By Vector Type
  - 8.3.8.2. Market Size and Forecast, By Workflow
  - 8.3.8.3. Market Size and Forecast, By Application
  - 8.3.8.4. Market Size and Forecast, By End User
- 8.3.9. UK Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.3.9.1. Market Size and Forecast, By Vector Type
  - 8.3.9.2. Market Size and Forecast, By Workflow
  - 8.3.9.3. Market Size and Forecast, By Application
  - 8.3.9.4. Market Size and Forecast, By End User
- 8.3.10. Italy Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.3.10.1. Market Size and Forecast, By Vector Type
  - 8.3.10.2. Market Size and Forecast, By Workflow
  - 8.3.10.3. Market Size and Forecast, By Application
  - 8.3.10.4. Market Size and Forecast, By End User
- 8.3.11. Spain Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.3.11.1. Market Size and Forecast, By Vector Type
  - 8.3.11.2. Market Size and Forecast, By Workflow
  - 8.3.11.3. Market Size and Forecast, By Application
  - 8.3.11.4. Market Size and Forecast, By End User
- 8.3.12. Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.3.12.1. Market Size and Forecast, By Vector Type
  - 8.3.12.2. Market Size and Forecast, By Workflow
  - 8.3.12.3. Market Size and Forecast, By Application
  - 8.3.12.4. Market Size and Forecast, By End User
8.4. Asia-Pacific
- 8.4.1. Key Market Trends and Opportunities
- 8.4.2. Market Size and Forecast, By Vector Type
- 8.4.3. Market Size and Forecast, By Workflow
- 8.4.4. Market Size and Forecast, By Application
- 8.4.5. Market Size and Forecast, By End User
- 8.4.6. Market Size and Forecast, By Country
- 8.4.7. Japan Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.4.7.1. Market Size and Forecast, By Vector Type
  - 8.4.7.2. Market Size and Forecast, By Workflow
  - 8.4.7.3. Market Size and Forecast, By Application
  - 8.4.7.4. Market Size and Forecast, By End User
- 8.4.8. China Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.4.8.1. Market Size and Forecast, By Vector Type
  - 8.4.8.2. Market Size and Forecast, By Workflow
  - 8.4.8.3. Market Size and Forecast, By Application
  - 8.4.8.4. Market Size and Forecast, By End User
- 8.4.9. Australia Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.4.9.1. Market Size and Forecast, By Vector Type
  - 8.4.9.2. Market Size and Forecast, By Workflow
  - 8.4.9.3. Market Size and Forecast, By Application
  - 8.4.9.4. Market Size and Forecast, By End User
- 8.4.10. India Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.4.10.1. Market Size and Forecast, By Vector Type
  - 8.4.10.2. Market Size and Forecast, By Workflow
  - 8.4.10.3. Market Size and Forecast, By Application
  - 8.4.10.4. Market Size and Forecast, By End User
- 8.4.11. South Korea Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.4.11.1. Market Size and Forecast, By Vector Type
  - 8.4.11.2. Market Size and Forecast, By Workflow
  - 8.4.11.3. Market Size and Forecast, By Application
  - 8.4.11.4. Market Size and Forecast, By End User
- 8.4.12. Rest of Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.4.12.1. Market Size and Forecast, By Vector Type
  - 8.4.12.2. Market Size and Forecast, By Workflow
  - 8.4.12.3. Market Size and Forecast, By Application
  - 8.4.12.4. Market Size and Forecast, By End User
8.5. LAMEA
- 8.5.1. Key Market Trends and Opportunities
- 8.5.2. Market Size and Forecast, By Vector Type
- 8.5.3. Market Size and Forecast, By Workflow
- 8.5.4. Market Size and Forecast, By Application
- 8.5.5. Market Size and Forecast, By End User
- 8.5.6. Market Size and Forecast, By Country
- 8.5.7. Brazil Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.5.7.1. Market Size and Forecast, By Vector Type
  - 8.5.7.2. Market Size and Forecast, By Workflow
  - 8.5.7.3. Market Size and Forecast, By Application
  - 8.5.7.4. Market Size and Forecast, By End User
- 8.5.8. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.5.8.1. Market Size and Forecast, By Vector Type
  - 8.5.8.2. Market Size and Forecast, By Workflow
  - 8.5.8.3. Market Size and Forecast, By Application
  - 8.5.8.4. Market Size and Forecast, By End User
- 8.5.9. South Africa Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.5.9.1. Market Size and Forecast, By Vector Type
  - 8.5.9.2. Market Size and Forecast, By Workflow
  - 8.5.9.3. Market Size and Forecast, By Application
  - 8.5.9.4. Market Size and Forecast, By End User
- 8.5.10. Rest of LAMEA Viral Vectors and Plasmid DNA Manufacturing Market
  - 8.5.10.1. Market Size and Forecast, By Vector Type
  - 8.5.10.2. Market Size and Forecast, By Workflow
  - 8.5.10.3. Market Size and Forecast, By Application
  - 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

10.1. Merck KGaA
- 10.1.1. Company Overview
- 10.1.2. Key Executives
- 10.1.3. Company Snapshot
- 10.1.4. Operating Business Segments
- 10.1.5. Product Portfolio
- 10.1.6. Business Performance
- 10.1.7. Key Strategic Moves and Developments
10.2. Lonza Group AG
- 10.2.1. Company Overview
- 10.2.2. Key Executives
- 10.2.3. Company Snapshot
- 10.2.4. Operating Business Segments
- 10.2.5. Product Portfolio
- 10.2.6. Business Performance
- 10.2.7. Key Strategic Moves and Developments
10.3. FUJIFILM Corporation
- 10.3.1. Company Overview
- 10.3.2. Key Executives
- 10.3.3. Company Snapshot
- 10.3.4. Operating Business Segments
- 10.3.5. Product Portfolio
- 10.3.6. Business Performance
- 10.3.7. Key Strategic Moves and Developments
10.4. Thermo Fisher Scientific
- 10.4.1. Company Overview
- 10.4.2. Key Executives
- 10.4.3. Company Snapshot
- 10.4.4. Operating Business Segments
- 10.4.5. Product Portfolio
- 10.4.6. Business Performance
- 10.4.7. Key Strategic Moves and Developments
10.5. Cobra Biologics
- 10.5.1. Company Overview
- 10.5.2. Key Executives
- 10.5.3. Company Snapshot
- 10.5.4. Operating Business Segments
- 10.5.5. Product Portfolio
- 10.5.6. Business Performance
- 10.5.7. Key Strategic Moves and Developments
10.6. Catalent Inc.
- 10.6.1. Company Overview
- 10.6.2. Key Executives
- 10.6.3. Company Snapshot
- 10.6.4. Operating Business Segments
- 10.6.5. Product Portfolio
- 10.6.6. Business Performance
- 10.6.7. Key Strategic Moves and Developments
10.7. WuXi Biologics.
- 10.7.1. Company Overview
- 10.7.2. Key Executives
- 10.7.3. Company Snapshot
- 10.7.4. Operating Business Segments
- 10.7.5. Product Portfolio
- 10.7.6. Business Performance
- 10.7.7. Key Strategic Moves and Developments
10.8. TakarBio Inc
- 10.8.1. Company Overview
- 10.8.2. Key Executives
- 10.8.3. Company Snapshot
- 10.8.4. Operating Business Segments
- 10.8.5. Product Portfolio
- 10.8.6. Business Performance
- 10.8.7. Key Strategic Moves and Developments
10.9. Waisman Biomanufacturing, LLC
- 10.9.1. Company Overview
- 10.9.2. Key Executives
- 10.9.3. Company Snapshot
- 10.9.4. Operating Business Segments
- 10.9.5. Product Portfolio
- 10.9.6. Business Performance
- 10.9.7. Key Strategic Moves and Developments
10.10. Genezen Laboratories
- 10.10.1. Company Overview
- 10.10.2. Key Executives
- 10.10.3. Company Snapshot
- 10.10.4. Operating Business Segments
- 10.10.5. Product Portfolio
- 10.10.6. Business Performance
- 10.10.7. Key Strategic Moves and Developments